Literature DB >> 19061095

Closing loopholes in the federal research regulations: some practical problems.

David B Resnik1.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 19061095      PMCID: PMC2650234          DOI: 10.1080/15265160802524660

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


× No keyword cloud information.
  9 in total

1.  Unregulated research with human subjects.

Authors:  Adil E Shamoo
Journal:  Account Res       Date:  1999       Impact factor: 2.622

2.  Why we need a national human experimentation agency.

Authors:  George J Annas
Journal:  Account Res       Date:  1999       Impact factor: 2.622

3.  Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit.

Authors:  David Wendler; Leah Belsky; Kimberly M Thompson; Ezekiel J Emanuel
Journal:  JAMA       Date:  2005-08-17       Impact factor: 56.272

4.  Quality-improvement research and informed consent.

Authors:  Franklin G Miller; Ezekiel J Emanuel
Journal:  N Engl J Med       Date:  2008-02-21       Impact factor: 91.245

5.  The new EPA regulations for protecting human subjects: haste makes waste.

Authors:  David B Resnik
Journal:  Hastings Cent Rep       Date:  2007 Jan-Feb       Impact factor: 2.683

6.  Universal and uniform protections of human subjects in research.

Authors:  Adil E Shamoo; Jack Schwartz
Journal:  Am J Bioeth       Date:  2008-11       Impact factor: 11.229

7.  The expanding purview: institutional review boards and the review of human subjects research.

Authors:  Jason Borenstein
Journal:  Account Res       Date:  2008 Jul-Sep       Impact factor: 2.622

8.  When is surgery research? Towards an operational definition of human research.

Authors:  C E Margo
Journal:  J Med Ethics       Date:  2001-02       Impact factor: 2.903

9.  How do institutional review boards apply the federal risk and benefit standards for pediatric research?

Authors:  Seema Shah; Amy Whittle; Benjamin Wilfond; Gary Gensler; David Wendler
Journal:  JAMA       Date:  2004-01-28       Impact factor: 56.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.